Coherus Oncology, Inc. Common Stock (CHRS) Stock
Key stats
- Market cap
- $90.00M
- Price / Earnings ratio
- -0.7x
- EPS (TTM)
- -$1.00
- Volume
- Loading
- 52-week high
- $2.62
- 52-week low
- $0.60
Source: third-party data provider, as of November 13, 2026
Compare with CHRS
Recent news
Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should Know
Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should Know
CHRS
Coherus Oncology Reports 89% Response Rate in Early ESCC Study
Coherus Oncology Reports 89% Response Rate in Early ESCC Study
CHRS
Coherus Oncology Q2 Earnings Call Highlights
Coherus Oncology Q2 Earnings Call Highlights
CHRS
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates
CHRSNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 30.34
- MACD 12/26/9
- -0.12
- EMA 9 of MACD
- -0.09
- MACD histogram
- -0.02
- SMA 50
- $1.09
- Price below SMA 50
- EMA 50
- $1.04
- Price below EMA 50
- SMA 200
- $1.49
- Price below SMA 200
- EMA 200
- $1.37
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should Know
Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should Know
CHRSCoherus Oncology Reports 89% Response Rate in Early ESCC Study
Coherus Oncology Reports 89% Response Rate in Early ESCC Study
CHRSCoherus Oncology Q2 Earnings Call Highlights
Coherus Oncology Q2 Earnings Call Highlights
CHRSCoherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates
CHRS
Coherus Oncology Q1 Earnings Call Highlights
Coherus Oncology Q1 Earnings Call Highlights
CHRS
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates
CHRS
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know
CHRS
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates
CHRS
2024 could turn into a ‘trader's market.' Here's how this strategist says you can make the most of that.
2024 could turn into a ‘trader's market.' Here's how this strategist says you can make the most of that.
CHRS
Coherus BioSciences launches biosimilar version of AbbVie's blockbuster Humira
Coherus BioSciences launches biosimilar version of AbbVie's blockbuster Humira
CHRSNews tone: automated (AI) classification of the article's content, not a price prediction.
About Coherus Oncology, Inc. Common Stock
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Dennis M. Lanfear | Chairman, President & CEO | 1955 |
| Dr. Theresa M. Lavallee Ph.D. | Chief Development Officer & Chairman of Scientific Advisory Board | 1966 |
| Mr. Bryan J. McMichael | Chief Financial Officer | 1979 |
| Ms. Carrie Graham | Vice President of Investor Relations & Advocacy | — |
| Mr. Andy Rittenberg | Chief Legal Officer | — |
| Ms. Rebecca Sunshine | Chief Human Resources Officer | 1963 |
| Mr. Michael Chen | Senior Vice President of Commercial Analytics & Trade | — |
| Dr. Rosh Dias M.D., MRCP | Chief Medical Officer | 1968 |
| Mr. Arvind Sood | Chief Strategy & Corporate Affairs Officer | — |
| Mr. Sameer Goregaoker | Chief Commercial Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 30.34
- MACD 12/26/9
- -0.12
- EMA 9 of MACD
- -0.09
- MACD histogram
- -0.02
- SMA 50
- $1.09
- Price below SMA 50
- EMA 50
- $1.04
- Price below EMA 50
- SMA 200
- $1.49
- Price below SMA 200
- EMA 200
- $1.37
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $7.00
- Average
- $7.50
- High
- $8.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.8 | -10.6 | ||||||||||
| 2022 | -24.7 | -6.7 | +12.4 | -29.6 | -24.2 | -1.6 | +8.2 | +22.1 | -13.3 | -7.2 | -21.7 | +18.4 |
| 2023 | -0.4 | -21.7 | +1.5 | -3.3 | -46.7 | +5.4 | +9.0 | +18.7 | -31.4 | -6.9 | -33.4 | +44.8 |
| 2024 | -31.5 | +9.1 | -0.8 | -18.3 | -11.7 | -1.7 | +3.1 | |||||
| 2026 | -7.3 | -23.0 | +2.4 | +2.3 | -11.7 | -10.8 | -2.1 | -6.2 | -11.7 | -28.4 | -22.7 |
